Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-7 (rhBMP-7/rhOP-1): Histological observations

Cristiano Susin, Mohammed Qahash, Giuseppe Polimeni, Ping Hung Lu, Hari S. Prasad, Michael D. Rohrer, Jan Hall, Ulf M E Wikesjö

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Pre-clinical studies have shown that recombinant human bone morphogenetic protein-2 (rhBMP-2) coated onto purpose-designed titanium porous-oxide surface implants induces clinically relevant bone formation and osseointegration. The objective of this study was to examine the potential of rhBMP-7, also known as recombinant human osteogenic protein-1 (rhOP-1), coated onto titanium porous-oxide surface implants to support vertical alveolar ridge augmentation and implant osseointegration. Materials and Methods: Bilateral, critical-size, 5 mm, supraalveolar peri-implant defects were created in six young adult Hound Labrador mongrel dogs. The animals received implants coated with rhBMP-7 at 1.5 or 3.0 mg/ml randomized to contra-lateral jaw quadrants. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants for primary intention healing. The animals received fluorescent bone markers at 3, 4, 7, and 8 weeks post-surgery when they were euthanized for histological evaluation. Results: Without striking differences between treatments, the implant sites exhibited a swelling that gradually regressed to become hard to palpation disguising the implant contours. The histological evaluation showed robust bone formation; the newly formed bone assuming characteristics of the contiguous resident bone, bone formation (height and area) averaging 4.1±1.0 versus 3.6±1.7 mm and 3.6±1.9 versus 3.1±1.8 mm2; and bone density 56% versus 50% for implants coated with rhBMP-7 at 1.5 and 3.0 mg/ml, respectively. Both treatments exhibited clinically relevant osseointegration, the corresponding bone-implant contact values averaging 51% and 47%. Notable peri-implant resident bone remodelling was observed for implants coated with rhBMP-7 at 3.0 mg/ml. Conclusions: rhBMP-7 coated onto titanium porous-oxide surface implants induces clinically relevant local bone formation including osseointegration and vertical augmentation of the alveolar ridge, the higher concentration/dose associated with some local side effects.

Original languageEnglish (US)
Pages (from-to)574-581
Number of pages8
JournalJournal of Clinical Periodontology
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Alveolar Ridge Augmentation
Osseointegration
Osteogenesis
Bone and Bones
Newfoundland and Labrador
Bone Remodeling
Palpation
Jaw
Bone Density
Young Adult
Dogs
human BMP7 protein
Therapeutics
titanium dioxide

Keywords

  • Alveolar augmentation
  • Bone morphogenetic protein
  • Dental/oral implants
  • Dogs
  • Osseointegration
  • RhBMP-7
  • RhOP-1
  • Seroma
  • Tissue engineering
  • Titanium
  • Titanium porous oxide

ASJC Scopus subject areas

  • Periodontics

Cite this

Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-7 (rhBMP-7/rhOP-1) : Histological observations. / Susin, Cristiano; Qahash, Mohammed; Polimeni, Giuseppe; Lu, Ping Hung; Prasad, Hari S.; Rohrer, Michael D.; Hall, Jan; Wikesjö, Ulf M E.

In: Journal of Clinical Periodontology, Vol. 37, No. 6, 01.06.2010, p. 574-581.

Research output: Contribution to journalArticle

Susin, Cristiano ; Qahash, Mohammed ; Polimeni, Giuseppe ; Lu, Ping Hung ; Prasad, Hari S. ; Rohrer, Michael D. ; Hall, Jan ; Wikesjö, Ulf M E. / Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-7 (rhBMP-7/rhOP-1) : Histological observations. In: Journal of Clinical Periodontology. 2010 ; Vol. 37, No. 6. pp. 574-581.
@article{5178875b4ccc4e29983305a5b24d4d6d,
title = "Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-7 (rhBMP-7/rhOP-1): Histological observations",
abstract = "Background: Pre-clinical studies have shown that recombinant human bone morphogenetic protein-2 (rhBMP-2) coated onto purpose-designed titanium porous-oxide surface implants induces clinically relevant bone formation and osseointegration. The objective of this study was to examine the potential of rhBMP-7, also known as recombinant human osteogenic protein-1 (rhOP-1), coated onto titanium porous-oxide surface implants to support vertical alveolar ridge augmentation and implant osseointegration. Materials and Methods: Bilateral, critical-size, 5 mm, supraalveolar peri-implant defects were created in six young adult Hound Labrador mongrel dogs. The animals received implants coated with rhBMP-7 at 1.5 or 3.0 mg/ml randomized to contra-lateral jaw quadrants. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants for primary intention healing. The animals received fluorescent bone markers at 3, 4, 7, and 8 weeks post-surgery when they were euthanized for histological evaluation. Results: Without striking differences between treatments, the implant sites exhibited a swelling that gradually regressed to become hard to palpation disguising the implant contours. The histological evaluation showed robust bone formation; the newly formed bone assuming characteristics of the contiguous resident bone, bone formation (height and area) averaging 4.1±1.0 versus 3.6±1.7 mm and 3.6±1.9 versus 3.1±1.8 mm2; and bone density 56{\%} versus 50{\%} for implants coated with rhBMP-7 at 1.5 and 3.0 mg/ml, respectively. Both treatments exhibited clinically relevant osseointegration, the corresponding bone-implant contact values averaging 51{\%} and 47{\%}. Notable peri-implant resident bone remodelling was observed for implants coated with rhBMP-7 at 3.0 mg/ml. Conclusions: rhBMP-7 coated onto titanium porous-oxide surface implants induces clinically relevant local bone formation including osseointegration and vertical augmentation of the alveolar ridge, the higher concentration/dose associated with some local side effects.",
keywords = "Alveolar augmentation, Bone morphogenetic protein, Dental/oral implants, Dogs, Osseointegration, RhBMP-7, RhOP-1, Seroma, Tissue engineering, Titanium, Titanium porous oxide",
author = "Cristiano Susin and Mohammed Qahash and Giuseppe Polimeni and Lu, {Ping Hung} and Prasad, {Hari S.} and Rohrer, {Michael D.} and Jan Hall and Wikesj{\"o}, {Ulf M E}",
year = "2010",
month = "6",
day = "1",
doi = "10.1111/j.1600-051X.2010.01554.x",
language = "English (US)",
volume = "37",
pages = "574--581",
journal = "Journal of Clinical Periodontology",
issn = "0303-6979",
publisher = "Blackwell Munksgaard",
number = "6",

}

TY - JOUR

T1 - Alveolar ridge augmentation using implants coated with recombinant human bone morphogenetic protein-7 (rhBMP-7/rhOP-1)

T2 - Histological observations

AU - Susin, Cristiano

AU - Qahash, Mohammed

AU - Polimeni, Giuseppe

AU - Lu, Ping Hung

AU - Prasad, Hari S.

AU - Rohrer, Michael D.

AU - Hall, Jan

AU - Wikesjö, Ulf M E

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Background: Pre-clinical studies have shown that recombinant human bone morphogenetic protein-2 (rhBMP-2) coated onto purpose-designed titanium porous-oxide surface implants induces clinically relevant bone formation and osseointegration. The objective of this study was to examine the potential of rhBMP-7, also known as recombinant human osteogenic protein-1 (rhOP-1), coated onto titanium porous-oxide surface implants to support vertical alveolar ridge augmentation and implant osseointegration. Materials and Methods: Bilateral, critical-size, 5 mm, supraalveolar peri-implant defects were created in six young adult Hound Labrador mongrel dogs. The animals received implants coated with rhBMP-7 at 1.5 or 3.0 mg/ml randomized to contra-lateral jaw quadrants. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants for primary intention healing. The animals received fluorescent bone markers at 3, 4, 7, and 8 weeks post-surgery when they were euthanized for histological evaluation. Results: Without striking differences between treatments, the implant sites exhibited a swelling that gradually regressed to become hard to palpation disguising the implant contours. The histological evaluation showed robust bone formation; the newly formed bone assuming characteristics of the contiguous resident bone, bone formation (height and area) averaging 4.1±1.0 versus 3.6±1.7 mm and 3.6±1.9 versus 3.1±1.8 mm2; and bone density 56% versus 50% for implants coated with rhBMP-7 at 1.5 and 3.0 mg/ml, respectively. Both treatments exhibited clinically relevant osseointegration, the corresponding bone-implant contact values averaging 51% and 47%. Notable peri-implant resident bone remodelling was observed for implants coated with rhBMP-7 at 3.0 mg/ml. Conclusions: rhBMP-7 coated onto titanium porous-oxide surface implants induces clinically relevant local bone formation including osseointegration and vertical augmentation of the alveolar ridge, the higher concentration/dose associated with some local side effects.

AB - Background: Pre-clinical studies have shown that recombinant human bone morphogenetic protein-2 (rhBMP-2) coated onto purpose-designed titanium porous-oxide surface implants induces clinically relevant bone formation and osseointegration. The objective of this study was to examine the potential of rhBMP-7, also known as recombinant human osteogenic protein-1 (rhOP-1), coated onto titanium porous-oxide surface implants to support vertical alveolar ridge augmentation and implant osseointegration. Materials and Methods: Bilateral, critical-size, 5 mm, supraalveolar peri-implant defects were created in six young adult Hound Labrador mongrel dogs. The animals received implants coated with rhBMP-7 at 1.5 or 3.0 mg/ml randomized to contra-lateral jaw quadrants. The mucoperiosteal flaps were advanced, adapted, and sutured to submerge the implants for primary intention healing. The animals received fluorescent bone markers at 3, 4, 7, and 8 weeks post-surgery when they were euthanized for histological evaluation. Results: Without striking differences between treatments, the implant sites exhibited a swelling that gradually regressed to become hard to palpation disguising the implant contours. The histological evaluation showed robust bone formation; the newly formed bone assuming characteristics of the contiguous resident bone, bone formation (height and area) averaging 4.1±1.0 versus 3.6±1.7 mm and 3.6±1.9 versus 3.1±1.8 mm2; and bone density 56% versus 50% for implants coated with rhBMP-7 at 1.5 and 3.0 mg/ml, respectively. Both treatments exhibited clinically relevant osseointegration, the corresponding bone-implant contact values averaging 51% and 47%. Notable peri-implant resident bone remodelling was observed for implants coated with rhBMP-7 at 3.0 mg/ml. Conclusions: rhBMP-7 coated onto titanium porous-oxide surface implants induces clinically relevant local bone formation including osseointegration and vertical augmentation of the alveolar ridge, the higher concentration/dose associated with some local side effects.

KW - Alveolar augmentation

KW - Bone morphogenetic protein

KW - Dental/oral implants

KW - Dogs

KW - Osseointegration

KW - RhBMP-7

KW - RhOP-1

KW - Seroma

KW - Tissue engineering

KW - Titanium

KW - Titanium porous oxide

UR - http://www.scopus.com/inward/record.url?scp=77952365345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952365345&partnerID=8YFLogxK

U2 - 10.1111/j.1600-051X.2010.01554.x

DO - 10.1111/j.1600-051X.2010.01554.x

M3 - Article

C2 - 20345394

AN - SCOPUS:77952365345

VL - 37

SP - 574

EP - 581

JO - Journal of Clinical Periodontology

JF - Journal of Clinical Periodontology

SN - 0303-6979

IS - 6

ER -